ARTICLE | Clinical News
CHMP recommends Imraldi biosimilar adalimumab
July 3, 2017 7:07 PM UTC
EMA’s CHMP recommended approval of Imraldi biosimilar adalimumab (SB5) from Samsung Bioepis Co. Ltd. to treat psoriasis and Crohn's disease (CD) in both adults and children, rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, hidradenitis suppurativa, ulcerative colitis (UC) and uveitis. The candidate is a biosimilar of Humira adalimumab from AbbVie Inc. (NYSE:ABBV). Humira is a human mAb against tumor necrosis factor (TNF) alpha...
BCIQ Target Profiles